PubMed Citation for id: 651848

Year	Number of Results
1990	1
1996	1
1998	1
2004	1
2005	1
2006	1
2007	1
2008	3
2009	2
2010	2
2011	1
2024	0

1

Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemic.

Euler Z, Bunnik EM, Burger JA, Boeser-Nunnink BD, Grijsen ML, Prins JM, Schuitemaker H. Euler Z, et al. J Virol. 2011 Jul;85(14):7236-45. doi: 10.1128/JVI.00196-11. Epub 2011 May 11. J Virol. 2011. PMID: 21561918 Free PMC article.

2

Small molecule mimetics of an HIV-1 gp41 fusion intermediate as vaccine leads.

Caulfield MJ, Dudkin VY, Ottinger EA, Getty KL, Zuck PD, Kaufhold RM, Hepler RW, McGaughey GB, Citron M, Hrin RC, Wang YJ, Miller MD, Joyce JG. Caulfield MJ, et al. J Biol Chem. 2010 Dec 24;285(52):40604-11. doi: 10.1074/jbc.M110.172197. Epub 2010 Oct 13. J Biol Chem. 2010. PMID: 20943652 Free PMC article.

3

Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16.

Doores KJ, Burton DR. Doores KJ, et al. J Virol. 2010 Oct;84(20):10510-21. doi: 10.1128/JVI.00552-10. Epub 2010 Aug 4. J Virol. 2010. PMID: 20686044 Free PMC article.

4

Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?

Stamatatos L, Morris L, Burton DR, Mascola JR. Stamatatos L, et al. Nat Med. 2009 Aug;15(8):866-70. doi: 10.1038/nm.1949. Nat Med. 2009. PMID: 19525964 Review.

5

Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S, Stamatatos L. Sather DN, et al. J Virol. 2009 Jan;83(2):757-69. doi: 10.1128/JVI.02036-08. Epub 2008 Nov 5. J Virol. 2009. PMID: 18987148 Free PMC article.

6

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, Decker JM, Wycuff D, Harris L, Hawkins N, Wood B, Nathe C, Richman D, Tomaras GD, Bibollet-Ruche F, Robinson JE, Morris L, Shaw GM, Montefiori DC, Mascola JR. Binley JM, et al. J Virol. 2008 Dec;82(23):11651-68. doi: 10.1128/JVI.01762-08. Epub 2008 Sep 24. J Virol. 2008. PMID: 18815292 Free PMC article.

7

The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.

Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT. Karlsson Hedestam GB, et al. Nat Rev Microbiol. 2008 Feb;6(2):143-55. doi: 10.1038/nrmicro1819. Nat Rev Microbiol. 2008. PMID: 18197170 Review.

8

Broad HIV-1 neutralization mediated by CD4-binding site antibodies.

Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, Louder MK, Wu X, Shaw GM, Connors M, Wyatt RT, Mascola JR. Li Y, et al. Nat Med. 2007 Sep;13(9):1032-4. doi: 10.1038/nm1624. Epub 2007 Aug 26. Nat Med. 2007. PMID: 17721546 Free PMC article.

9

Role of neutralizing antibodies in protective immunity against HIV.

Srivastava IK, Ulmer JB, Barnett SW. Srivastava IK, et al. Hum Vaccin. 2005 Mar-Apr;1(2):45-60. doi: 10.4161/hv.1.2.1764. Epub 2005 Mar 17. Hum Vaccin. 2005. PMID: 17038830 Review.

10

Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Haynes BF, Montefiori DC. Haynes BF, et al. Expert Rev Vaccines. 2006 Aug;5(4):579-95. doi: 10.1586/14760584.5.4.579. Expert Rev Vaccines. 2006. PMID: 16989638 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

14 results

Results by year